Ascentage Pharma, a global biopharmaceutical company specializing in novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, has announced its participation in the 42nd J.P. Morgan Healthcare Conference. Dr. Dajun Yang, the Chairman and CEO of Ascentage Pharma, is scheduled to present at the conference on January 11, 2024, at 2:00 AM Beijing Time (January 10, 2024, at 10:00 AM Pacific Time).
The J.P. Morgan Healthcare Conference is a prominent annual event that serves as a key gathering for the global pharmaceutical industry and the investment community. Taking place in San Francisco, CA, from January 8 to 11, the conference provides an influential platform for industry leaders to share insights and advancements.
Dr. Dajun Yang’s presentation at the conference is expected to shed light on Ascentage Pharma’s contributions to the field, particularly its innovative therapies targeting cancer, CHB, and age-related diseases. The company’s focus on developing therapeutics inhibiting protein-protein interactions to restore apoptosis (programmed cell death) sets it apart in the biopharmaceutical landscape.
Interested parties can register for the conference and view a live webcast of Dr. Yang’s presentation on the official J.P. Morgan Healthcare Conference website. An archived replay will also be available for 30 days following the event.
Ascentage Pharma, listed on the Main Board of the Stock Exchange of Hong Kong Limited (6855.HK), has established a robust pipeline of nine clinical drug candidates. These include potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates targeting IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). The company is actively conducting over 40 Phase I/II clinical trials globally, reflecting its commitment to advancing therapeutic solutions.
Notably, Ascentage Pharma has received designations such as Priority Review, Breakthrough Therapy, Orphan Drug, and Fast Track from regulatory authorities, underscoring the significance of its core drug candidate, olverembatinib, in treating drug-resistant chronic myeloid leukemia (CML).
The company’s strategic approach includes collaboration with renowned biotechnology and pharmaceutical entities globally, demonstrating its commitment to fostering innovation in drug discovery and development. As it continues to strengthen its research and development capabilities, Ascentage Pharma aims to address unmet clinical needs and contribute to global healthcare advancements.